[{"orgOrder":0,"company":"National Health Research Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"DBPR115","moa":"Cancer Cell membrane protein-phosphatidyl serine","graph1":"Oncology","graph2":"Phase I","graph3":"National Health Research Institutes","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Health Research Institutes \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"National Health Research Institutes \/ Not Applicable"},{"orgOrder":0,"company":"National Health Research Institutes","sponsor":"Anbogen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"DBPR112","moa":"RTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Health Research Institutes","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Health Research Institutes \/ National Health Research Institutes","highestDevelopmentStatusID":"7","companyTruncated":"National Health Research Institutes \/ National Health Research Institutes"}]

Find Clinical Drug Pipeline Developments & Deals by National Health Research Institutes

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : ABT-101 (DBPR112) demonstrates excellent therapeutic potential and superior safety profile compared to competitors that are under clinical development. It meets challenges of unmet medical needs for cancer drugs targeting exon 20 insertions in HER2.

                          Brand Name : ABT-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 13, 2022

                          Lead Product(s) : DBPR112

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Anbogen Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : DBPR115 small molecule drug delivery system has a lower production cost and is less likely to cause adverse immune reactions.

                          Brand Name : DBPR115

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 18, 2021

                          Lead Product(s) : DBPR115

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank